

Rebecca Borella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7177532/publications.pdf>

Version: 2024-02-01

11
papers

1,028
citations

1040056

9
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

2766
citing authors

#	ARTICLE	IF	CITATIONS
1	Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. <i>Nature Communications</i> , 2020, 11, 3434.	12.8	636
2	Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia. <i>EMBO Molecular Medicine</i> , 2020, 12, e13001.	6.9	133
3	Expansion of plasmablasts and loss of memory B cells in peripheral blood from COVID-19 patients with pneumonia. <i>European Journal of Immunology</i> , 2020, 50, 1283-1294.	2.9	95
4	Metabolic reprogramming shapes neutrophil functions in severe COVID-19. <i>European Journal of Immunology</i> , 2022, 52, 484-502.	2.9	34
5	Cell Death in Coronavirus Infections: Uncovering Its Role during COVID-19. <i>Cells</i> , 2021, 10, 1585.	4.1	33
6	Molecular and cellular immune features of aged patients with severe COVID-19 pneumonia. <i>Communications Biology</i> , 2022, 5, .	4.4	27
7	Handling and Processing of Blood Specimens from Patients with COVID-19 for Safe Studies on Cell Phenotype and Cytokine Storm. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2020, 97, 668-673.	1.5	26
8	Mitochondrial damage-associated molecular patterns stimulate reactive oxygen species production in human microglia. <i>Molecular and Cellular Neurosciences</i> , 2020, 108, 103538.	2.2	15
9	Plasma Cytokine Atlas Reveals the Importance of TH2 Polarization and Interferons in Predicting COVID-19 Severity and Survival. <i>Frontiers in Immunology</i> , 2022, 13, 842150.	4.8	15
10	Impaired Mitochondrial Morphology and Functionality in <i>Lonp1wt/Δ</i> Mice. <i>Journal of Clinical Medicine</i> , 2020, 9, 1783.	2.4	12
11	Redistribution of <i>CD8</i> ⁺ T cell subsets in metastatic renal cell carcinoma patients treated with <i>anti-CTLA-4</i> therapy. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2022, 101, 597-605.	1.5	2